Core Viewpoint - 基石药业-B (02616) is preparing to present clinical data for its drug candidates CS2009 and CS5001 at the upcoming ESMO annual meeting in October 2025, highlighting its advancements in cancer treatment [1] Group 1: Clinical Trials and Data - CS2009, a tri-specific antibody targeting PD-1/VEGF/CTLA-4, has preliminary data from a Phase I dose-escalation study involving 9 patients, which will be presented at the ESMO conference [1] - The company will showcase initial data from approximately 70 patients with advanced solid tumors for CS2009, marking the first known clinical data release globally for this tri-specific antibody [1] - CS5001, an antibody-drug conjugate targeting ROR1, has its Phase Ib clinical study design summary published on the ESMO website [1]
基石药业-B(02616)将公布PD-1/VEGF/CTLA-4三抗I期剂量递增临床数据和ROR1 ADC最新研究设计